
BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co (NYSE:BMY) shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).
Among 38 evaluable patients, the regimen achieved a 76.3% confirmed overall response rate (85% at 20 mg/kg; 66.7% at 30 mg/kg) and a 100% disease control rate, with average tumor shrinkage of 56.7% and nearly 90% showing early tumor shrinkage.